中信证券股份有限公司 关于南京科思化学股份有限公司 开展外汇衍生品投资业务的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐机构"、"保荐人"） 作为南京科思化学股份有限公司（以下简称"科思股份"、"公司"）首次公开发 行股票并在创业板上市持续督导工作以及向不特定对象发行可转换公司债券的 保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交易所创业板股 票上市规则（2024 年修订）》《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》及《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等相关法律、法规和规范性文件的规定，对科思股份开展外汇 衍生品投资业务进行了核查，核查情况及核查意见如下： 一、2024 年度外汇衍生品投资的具体情况 公司对 2024 年度外汇衍生品投资损益情况进行了确认，报告期内，公司未 发生远期结售汇交易，期初、期末无余额。 二、内控制度执行情况 公司制定了《远期外汇交易业务暂行办法》，对远期结汇业务的操作原则、 审批权限、内部操作流程等作出明确规定，有效规范远期结售汇业务行为。2024 年度，公司未发生远期结售汇交易，未出现违反相关 ...

中信证券股份有限公司 关于南京科思化学股份有限公司 2024 年度募集资金存放与使用情况的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐机构"、"保荐人"） 作为南京科思化学股份有限公司（以下简称"科思股份"、"公司"）首次公开发 行股票并在创业板上市持续督导工作以及向不特定对象发行可转换公司债券的 保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交易所创业板股 票上市规则（2024 年修订）》《上市公司监管指引第 2 号——上市公司募集资金 管理和使用的监管要求》《深圳证券交易所上市公司自律监管指引第 2 号——创 业板上市公司规范运作》及《深圳证券交易所上市公司自律监管指引第 13 号— —保荐业务》等有关规定，对科思股份 2024 年度募集资金的存放与使用情况进 行了核查，具体情况如下： 一、募集资金基本情况 （一）首次公开发行股票募集资金 1、实际募集资金金额及到位情况 根据中国证券监督管理委员会证监许可[2020]803 号《关于核准南京科思化 学股份有限公司首次公开发行股票的批复》文件核准，公司向社会公众公开发行 人民币普通股（A 股）2,822 万股，每股面值 1.00 元 ...

中信证券股份有限公司 关于南京科思化学股份有限公司 开展以套期保值为目的的远期结售汇业务的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐机构"、"保荐人"） 作为南京科思化学股份有限公司（以下简称"科思股份"、"公司"）首次公开发 行股票并在创业板上市持续督导工作以及向不特定对象发行可转换公司债券的 保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交易所创业板股 票上市规则（2024 年修订）》《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作（2023 年修订）》及《深圳证券交易所上市公司自律 监管指引第 13 号——保荐业务》等相关法律、法规和规范性文件的规定，对科 思股份开展以套期保值为目的的远期结售汇业务的事项进行了核查，核查情况及 核查意见如下： 一、远期结售汇业务概述 （一）目的 由于公司国际业务的外汇收付金额较大，为减少外汇汇率波动带来的风险， 公司拟开展远期结售汇业务。本次开展远期结售汇业务，将遵循稳健原则，不进 行以投机和盈利为目的的外汇交易，上述业务均以正常生产经营为基础，与公司 日常经营需求紧密相关，交易的资金使用安排具备合理性，以规避和防范 ...

2024 年度独立董事述职报告 南京科思化学股份有限公司 2024 年度独立董事述职报告 宋 兵 本人具体工作履历、专业背景以及兼职情况详见公司《2024 年年度报告》中 第四节"公司治理"。 报告期内，本人任职符合《上市公司独立董事管理办法》第六条规定的独立 性要求，不存在影响独立性的情况。 二、独立董事年度履职概况 （一）出席董事会和股东大会会议情况 2024 年度，公司共计召开了 6 次董事会和 1 次股东大会。本人出席董事会 及股东大会的情况如下： | | | 董事会出席情况 | | | | | | --- | --- | --- | --- | --- | --- | --- | | 本报告期 | 现场出 | 以通讯方 | 委托出 | 缺席董 | 是否连续 两次未亲 | 出席股 东大会 | | 应参加董 | 席董事 | 式参加董 | 席董事 | 事会次 | | 次数 | | 事会次数 | 会次数 | 事会次数 | 会次数 | 数 | 自参加董 事会会议 | | | 6 | 0 | 6 | 0 | 0 | 否 | 0 | 各位股东及股东代表： 本人作为南京科思化学股份有限公司（以下简称"公司"）第三届 ...

董事会关于独立董事独立性情况的专项意见 关于独立董事独立性情况的专项意见 根据《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》等要求，南京科思化学股份有限公司 （以下简称"公司"）董事会就公司在任独立董事宋兵、聂长海、俞健的独立性 情况进行评估并出具如下专项意见： 经核查独立董事宋兵、聂长海、俞健的任职经历以及签署的相关自查文件， 2024 年度上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要 股东担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其 进行独立客观判断的关系，不存在其他影响独立董事独立性的情况。公司董事会 认为公司独立董事符合《上市公司独立董事管理办法》《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》中关于独立董事的任职资 格及独立性的要求。 南京科思化学股份有限公司 董 事 会 2025 年 4 月 22 日 南京科思化学股份有限公司董事会 ...

Financial Performance - The company's revenue for Q1 2025 was ¥396,565,101.90, a decrease of 44.29% compared to ¥711,843,765.01 in the same period last year[5] - Net profit attributable to shareholders was ¥48,012,324.67, down 78.15% from ¥219,777,234.42 year-on-year[5] - Basic earnings per share decreased to ¥0.1413, down 78.23% from ¥0.6490 in the same period last year[6] - Net profit for the period was ¥47,831,962.27, down from ¥219,594,280.34, reflecting a decline of approximately 78.2% year-over-year[25] - Total operating revenue decreased to ¥396,565,101.90 from ¥711,843,765.01, representing a decline of approximately 44.2% year-over-year[23] - Total operating costs reduced to ¥348,403,031.35 from ¥474,115,510.18, a decrease of about 26.5% year-over-year[24] Cash Flow - The net cash flow from operating activities was -¥11,863,860.94, a decline of 107.36% compared to ¥161,229,326.64 in the previous year[6] - Cash flow from operating activities showed a net outflow of ¥11,863,860.94 compared to a net inflow of ¥161,229,326.64 in the previous period[27] - Cash inflow from investment activities was ¥547,000,000.00, slightly up from ¥530,000,000.00 in the previous period[27] - Net cash flow from investing activities was $7.85 million, compared to a negative cash flow of $153.12 million in the previous period[28] - Total cash inflow from financing activities was $1.29 million, a decrease from $29.73 million year-over-year[28] - Cash and cash equivalents at the end of the period totaled $515.42 million, down from $572.64 million in the previous year[28] - The company reported a net increase in cash and cash equivalents of $1.29 million, compared to $41.46 million in the previous period[28] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥4,133,497,375.65, a decrease of 2.93% from ¥4,258,154,997.78 at the end of the previous year[6] - Total current assets decreased from CNY 2,064,657,895.12 to CNY 1,864,592,470.16, a decline of approximately 9.7%[19] - Total liabilities decreased from CNY 589,394,486.71 to CNY 412,789,190.79, a reduction of approximately 30%[21] - Total liabilities decreased to ¥1,196,735,259.66 from ¥1,376,370,011.64, a reduction of approximately 13.1%[24] - Total equity increased to ¥2,936,762,115.99 from ¥2,881,784,986.14, an increase of about 1.9%[24] - The company’s total equity remains stable despite fluctuations in assets and liabilities, indicating a solid financial foundation[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 22,972[12] - The largest shareholder, Nanjing Kesi Investment Development Co., Ltd., holds 52.00% of the shares[13] - The company has a total of 13,673,550 shares under lock-up agreements, with a portion being released annually[17] Other Financial Metrics - The gross margin of the main business decreased due to price reductions in response to market changes, impacting net profit and earnings per share[11] - The company experienced a decline in sales volume of sunscreen products due to a slowdown in market demand and increased competition[11] - The company reported a total of ¥4,042,207.26 in non-recurring gains and losses for the period[8] - Deferred income tax liabilities decreased to ¥86,545,258.26 from ¥97,943,435.48, a decline of approximately 11.6%[24] - Other comprehensive income after tax showed a negative amount of ¥581,397.69 compared to a positive amount of ¥609,374.06 in the previous period[25] - The company made cash payments of $153.10 million for fixed assets, intangible assets, and other long-term assets, down from $222.96 million[28] - Cash outflow from investing activities totaled $543.10 million, a decrease from $687.96 million year-over-year[28] Accounting and Reporting - The first quarter report was not audited, indicating preliminary financial results[29] - The company has not yet adopted the new accounting standards effective from 2025[28]

Dividend and Profit Distribution - The company plans to distribute a cash dividend of 3 RMB per 10 shares to all shareholders, based on a total of 339,776,037 shares[3]. - The company will increase capital reserves by converting 4 shares for every 10 shares held by shareholders[3]. - The 2024 annual profit distribution proposal includes a cash dividend of RMB 3.00 per 10 shares, totaling RMB 101,932,811.10, with a capital reserve increase of 4 shares for every 10 shares held, raising total share capital to 475,686,451 shares[161]. - The company’s cash dividend policy requires a minimum of 20% of profit distribution for companies in a growth phase with significant capital expenditure plans[160]. - The company’s cash dividend distribution is compliant with relevant laws, regulations, and its articles of association[159]. - The company’s board of directors actively engages with shareholders, especially minority shareholders, to gather opinions on profit distribution plans[156]. - The company’s independent directors have the right to express opinions if they believe the cash dividend plan may harm the company or minority shareholders[156]. - The company’s profit distribution policy can be adjusted based on significant changes in operational conditions or external environments, subject to compliance with regulatory requirements[156]. - The company’s cash dividend distribution plan for 2024 is expected to be completed within two months after the shareholders' meeting approval[161]. - The company has proposed a profit distribution plan for 2024 that aligns with its actual situation and complies with relevant laws and regulations, ensuring no impact on operations and benefiting all shareholders[162]. Financial Performance - The company reported a strong performance in the fiscal year 2024, with a projected revenue growth of 15% compared to the previous year[12]. - The company's operating revenue for 2024 was ¥2,275,984,587.88, a decrease of 5.16% compared to ¥2,399,920,217.58 in 2023[17]. - Net profit attributable to shareholders for 2024 was ¥562,473,383.41, down 23.33% from ¥733,587,263.70 in 2023[17]. - The basic earnings per share for 2024 was ¥1.6588, reflecting a decline of 23.43% from ¥2.1663 in 2023[17]. - The company's diluted earnings per share for 2024 was ¥1.5791, down 22.92% from ¥2.0487 in 2023[17]. - The weighted average return on equity decreased to 20.75% in 2024 from 32.15% in 2023, a drop of 11.40%[17]. - The company's comprehensive gross margin decreased to 44.40%, reflecting a decline due to reduced product prices and market demand[50]. - The company reported a total revenue of 7,500,000,000 for the reporting period, with a net profit of 2,000,000,000, reflecting a significant growth compared to the previous year[127]. Market and Product Development - User data indicates a significant increase in customer engagement, with a 25% rise in active users year-over-year[12]. - The company anticipates a robust outlook for 2025, forecasting an additional 20% revenue growth driven by new product launches and market expansion[12]. - New product development includes the introduction of advanced UV protection agents, which are expected to enhance market competitiveness[12]. - The company is focusing on expanding its market presence in Southeast Asia, targeting a 30% increase in market share within the next two years[12]. - Strategic acquisitions are planned to bolster the company's product portfolio, with an estimated investment of $50 million allocated for this purpose[12]. - The company is currently developing several new products, including physical sunscreen agents and high-end moisturizing agents, to expand its product offerings in the personal care sector[69]. - The company has expanded its product offerings to include amino acid surfactants and other personal care ingredients, enhancing its competitive position in the market[48]. - The company is focusing on market expansion strategies in the personal care segment, targeting a 1% increase in market share[97]. Research and Development - The company aims to enhance its R&D capabilities, increasing the budget by 40% to support innovation in chemical formulations[12]. - The company is investing in research and development to innovate raw materials and formulations, particularly in enhancing UVA protection technology, which is a key future direction for the industry[31]. - Research and development expenses for 2024 totaled ¥115,952,558.44, representing 5.09% of operating revenue, up from 4.72% in 2023[69]. - The number of R&D personnel increased by 1.94% to 316, with a notable rise in the number of master's degree holders by 48.84%[69]. - The company holds 203 authorized patents, including 59 invention patents, showcasing its strong R&D capabilities and multi-layered technological reserves[44]. Environmental and Sustainability Initiatives - The company is committed to environmental sustainability by adopting advanced pollution control technologies and exploring green chemical processes to reduce environmental impact[33]. - The company has implemented environmental impact assessments for all construction projects as per regulatory requirements[175]. - The company has been actively reducing carbon emissions through advanced equipment and technology upgrades since 2017, with annual disclosures to CDP (Carbon Disclosure Project) regarding greenhouse gas management and performance[183]. - The company has not experienced any environmental pollution incidents or complaints during the reporting period[177]. - The company has developed emergency response plans and conducted various emergency drills to enhance preparedness for environmental incidents[180]. Governance and Compliance - The company has a structured governance framework, ensuring compliance with legal standards and protecting shareholder rights[118]. - The board of directors consists of 9 members, including 3 independent directors, ensuring a balanced governance structure[119]. - The company maintains complete independence in assets, personnel, finance, organization, and business from its controlling shareholders and related parties[121]. - The company has established necessary internal supervision mechanisms to ensure compliance and asset security[168]. - The company’s governance structure complies with legal and regulatory requirements without significant discrepancies[120]. Risk Management - The management discussed potential risks and countermeasures in the section on future development outlook[3]. - The company acknowledges risks from industry and market fluctuations, which could impact performance due to changes in macroeconomic conditions and downstream market demand[111]. - The company is actively monitoring raw material price fluctuations and has implemented measures to mitigate their impact on profitability[111]. - High customer concentration poses a risk, as major clients like DSM-Firmenich and L'Oréal account for a significant portion of sales; any changes in their purchasing behavior could impact revenue[113]. - International market risks are present, particularly due to trade tensions, such as the U.S. imposing tariffs on Chinese products, which could affect export performance[113]. Employee and Management Compensation - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 12 million[139]. - The highest remuneration was received by the Chairman, Zhou Xuming, totaling CNY 1.38 million[140]. - The company’s management compensation system includes a basic salary and an annual performance bonus, with the latter based on annual performance assessments[167]. - The company has implemented a long-term incentive mechanism through the 2023 restricted stock incentive plan, optimizing the performance evaluation system for senior management[167]. - The company has established a salary system that includes annual salary and monthly salary structures, with performance-based incentives for different departments[150]. Strategic Partnerships and Acquisitions - The company is actively pursuing mergers and acquisitions to enhance its competitive edge in the market[132]. - The company has established strategic partnerships with key industry players to leverage synergies and drive innovation[132]. - The company is committed to enhancing its market presence through strategic partnerships and acquisitions in the chemical sector[95]. Financial Management and Fund Utilization - The company plans to actively explore the market to enhance profitability and increase sales revenue[192]. - The company aims to strengthen internal management to control costs and improve operational efficiency[192]. - The company will adopt various measures to ensure effective use of raised funds and mitigate risks of dilution of immediate returns[192]. - The company has established a three-year shareholder dividend return plan following its IPO on the ChiNext board, aiming to enhance shareholder returns based on operational performance and development plans[193]. - The company will ensure timely and full compensation to investors for any losses incurred due to misleading statements in the IPO documents[191].

证券代码：300856 证券简称：科思股份 公告编号：2025-017 债券代码：123192 债券简称：科思转债 南京科思化学股份有限公司 关于开展以套期保值为目的的远期结售汇业务的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1、交易目的：为减少外汇汇率波动带来的风险，南京科思化学 股份有限公司（以下简称"公司"）拟开展远期结售汇业务，不进行 以投机和盈利为目的的外汇交易，上述业务均以正常生产经营为基础， 与公司日常经营需求紧密相关，交易的资金使用安排具备合理性，以 规避和防范汇率风险为目的，不影响公司主营业务的发展。 2、交易品种及金额:不超过 4 亿元人民币（或等值外币）的远期 结售汇。 3、交易场所：与公司不存在关联关系的境内金融机构。 4、已履行及拟履行的审议程序：公司于 2025 年 4 月 22 日召开 第三届董事会第二十三次会议和第三届监事会第二十次会议，审议通 过了《关于开展以套期保值为目的的远期结售汇业务的议案》，本次 交易不涉及关联交易。本议案在公司董事会决策权限范围内，无需提 交公司股东大会审议。 5、风险提示 ...

董事会审计委员会对会计师事务所 2024 年度履职评估及履行监督职责情况的报告 南京科思化学股份有限公司 董事会审计委员会对会计师事务所 2024 年度履职评估 及履行监督职责情况的报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准 则》《国有企业、上市公司选聘会计师事务所管理办法》和南京科思化学股份有 限公司（以下简称"公司"）的《公司章程》《董事会审计委员会工作细则》等规 定和要求，董事会审计委员会本着勤勉尽责的原则，恪尽职守，认真履职。现将 董事会审计委员会对会计师事务所 2024 年度履职评估及履行监督职责的情况汇 报如下： 等行业。 本公司同行业上市公司审计客户家数 9 家 （二）聘任会计师事务所履行的程序 公司于 2024 年 4 月 16 日和 2024 年 5 月 7 日分别召开第三届董事会第十八 次会议和 2023 年度股东大会，审议通过了《关于续聘天衡会计师事务所（特殊 普通合伙）为公司 2024 年度审计机构的议案》，同意续聘天衡会计师事务所（特 殊普通合伙）（以下简称"天衡会计师事务所"）为公司 2024 年度审计机构，聘 期一年。 二、2024 年年审会计师事 ...